RxDoctor Payments Data

Anna Kemner

Nurse Practitioner · Saint Louis, MONPI 1871192781

Payments from drug & device makers

$5,376in general payments, 2019–2025

Across 283 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Ardelyx, Inc.$408
  • Takeda Pharmaceuticals U.S.A., Inc.$361
  • QOL Medical, LLC$195
  • Pfizer$190
  • plus $982 from 17 others

What the payments were for

  • Food & beverage$5,376100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,376 in reported general payments places this provider in the 90th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$31,423
Medicare patients
302
Services billed
445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase28$80,111
LinzessLinaclotide27$34,774
TrulancePlecanatide19$23,557
Mesalamine20$12,706
Colestipol Hcl51$5,867
Sucralfate20$3,310
Pantoprazole Sodium192$2,406
Famotidine140$1,993
Omeprazole131$1,478
Nortriptyline Hcl30$620
Dicyclomine Hcl45$509
Azathioprine11$380
Mirtazapine16$299
Prochlorperazine Maleate11$236
Ondansetron Hcl22$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,133$114,88555 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$1,107$23,55719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →